-
XW02 Muscle
-
XW020 Open
-
XW0200 Brexanolone
-
XW0200 Spesolimab Monoclonal Antibody
-
XW0201 Daratumumab and Hyaluronidase-fihj
-
XW0201 Eladocagene exuparvovec
-
XW0202 Bromelain-enriched Proteolytic Enzyme
-
XW0202 Nerinitide
-
XW0203 Durvalumab Antineoplastic
-
XW0203 Maribavir Anti-infective
-
XW0204 Teclistamab Antineoplastic
-
XW0205 Mosunetuzumab Antineoplastic
-
XW0205 Narsoplimab Monoclonal Antibody
-
XW0206 Afamitresgene Autoleucel Immunotherapy
-
XW0206 Lefamulin Anti-infective
-
XW0206 Terlipressin
-
XW0207 Coagulation Factor Xa, Inactivated
-
XW0207 Tabelecleucel Immunotherapy
-
XW0207 Trilaciclib
-
XW0208 Lurbinectedin
-
XW0208 Mineral-based Topical Hemostatic Agent
-
XW0208 Treosulfan
-
XW0208 Uridine Triacetate
-
XW0209 Ceftolozane/Tazobactam Anti-infective
-
XW0209 Inebilizumab-cdon
-
XW0209 Satralizumab-mwge
-
XW020A Cefiderocol Anti-infective
-
XW020A Ciltacabtagene Autoleucel
-
XW020B Amivantamab Monoclonal Antibody
-
XW020B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW020B Omadacycline Anti-infective
-
XW020C Eculizumab
-
XW020C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW020D Atezolizumab Antineoplastic
-
XW020D8Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
-
-
XW020D Engineered Allogeneic Thymus Tissue
-
XW020D8Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
-
-
XW020E Etesevimab Monoclonal Antibody
-
XW020E Remdesivir Anti-infective
-
XW020F Bamlanivimab Monoclonal Antibody
-
XW020F Other New Technology Therapeutic Substance
-
XW020G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW020G Plazomicin Anti-infective
-
XW020G REGN-COV2 Monoclonal Antibody
-
XW020G Sarilumab
-
XW020H Axicabtagene Ciloleucel Immunotherapy
-
XW020H Other New Technology Monoclonal Antibody
-
XW020H Synthetic Human Angiotensin II
-
XW020H Tocilizumab
-
XW020J Apalutamide Antineoplastic
-
XW020J Tisagenlecleucel Immunotherapy
-
XW020K Fosfomycin Anti-infective
-
XW020K Idecabtagene Vicleucel Immunotherapy
-
XW020K Leronlimab Monoclonal Antibody
-
XW020L CD24Fc Immunomodulator
-
XW020L Erdafitinib Antineoplastic
-
XW020L Lifileucel Immunotherapy
-
XW020M Baricitinib
-
XW020M Brexucabtagene Autoleucel Immunotherapy
-
XW020M Esketamine Hydrochloride
-
XW020N Lisocabtagene Maraleucel Immunotherapy
-
XW020N Meropenem-vaborbactam Anti-infective
-
XW020P Antibiotic-eluting Bone Void Filler
-
XW020Q Tagraxofusp-erzs Antineoplastic
-
XW020R Fostamatinib
-
XW020R Venetoclax Antineoplastic
-
XW020S COVID-19 Vaccine Dose 1
-
XW020S Iobenguane I-131 Antineoplastic
-
XW020T COVID-19 Vaccine Dose 2
-
XW020T Ruxolitinib
-
XW020U COVID-19 Vaccine
-
XW020U Imipenem-cilastatin-relebactam Anti-infective
-
XW020V COVID-19 Vaccine Dose 3
-
XW020V Gilteritinib Antineoplastic
-
XW020W Caplacizumab
-
XW020W COVID-19 Vaccine Booster
-
XW020X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW020X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW020Y Other New Technology Monoclonal Antibody
-
-
XW023 Percutaneous
-
XW0230 Brexanolone
-
XW0230 Spesolimab Monoclonal Antibody
-
XW0231 Daratumumab and Hyaluronidase-fihj
-
XW0231 Eladocagene exuparvovec
-
XW0232 Bromelain-enriched Proteolytic Enzyme
-
XW0232 Nerinitide
-
XW0233 Durvalumab Antineoplastic
-
XW0233 Maribavir Anti-infective
-
XW0234 Teclistamab Antineoplastic
-
XW0235 Mosunetuzumab Antineoplastic
-
XW0235 Narsoplimab Monoclonal Antibody
-
XW0236 Afamitresgene Autoleucel Immunotherapy
-
XW0236 Lefamulin Anti-infective
-
XW0236 Terlipressin
-
XW0237 Coagulation Factor Xa, Inactivated
-
XW0237 Tabelecleucel Immunotherapy
-
XW0237 Trilaciclib
-
XW0238 Lurbinectedin
-
XW0238 Mineral-based Topical Hemostatic Agent
-
XW0238 Treosulfan
-
XW0238 Uridine Triacetate
-
XW0239 Ceftolozane/Tazobactam Anti-infective
-
XW0239 Inebilizumab-cdon
-
XW0239 Satralizumab-mwge
-
XW023A Cefiderocol Anti-infective
-
XW023A Ciltacabtagene Autoleucel
-
XW023B Amivantamab Monoclonal Antibody
-
XW023B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW023B Omadacycline Anti-infective
-
XW023C Eculizumab
-
XW023C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW023D Atezolizumab Antineoplastic
-
XW023D Engineered Allogeneic Thymus Tissue
-
XW023E Etesevimab Monoclonal Antibody
-
XW023E Remdesivir Anti-infective
-
XW023F Bamlanivimab Monoclonal Antibody
-
XW023F Other New Technology Therapeutic Substance
-
XW023G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW023G Plazomicin Anti-infective
-
XW023G REGN-COV2 Monoclonal Antibody
-
XW023G Sarilumab
-
XW023H Axicabtagene Ciloleucel Immunotherapy
-
XW023H Other New Technology Monoclonal Antibody
-
XW023H Synthetic Human Angiotensin II
-
XW023H Tocilizumab
-
XW023J Apalutamide Antineoplastic
-
XW023J Tisagenlecleucel Immunotherapy
-
XW023K Fosfomycin Anti-infective
-
XW023K Idecabtagene Vicleucel Immunotherapy
-
XW023K Leronlimab Monoclonal Antibody
-
XW023L CD24Fc Immunomodulator
-
XW023L Erdafitinib Antineoplastic
-
XW023L Lifileucel Immunotherapy
-
XW023M Baricitinib
-
XW023M Brexucabtagene Autoleucel Immunotherapy
-
XW023M Esketamine Hydrochloride
-
XW023N Lisocabtagene Maraleucel Immunotherapy
-
XW023N Meropenem-vaborbactam Anti-infective
-
XW023P Antibiotic-eluting Bone Void Filler
-
XW023Q Tagraxofusp-erzs Antineoplastic
-
XW023R Fostamatinib
-
XW023R Venetoclax Antineoplastic
-
XW023S COVID-19 Vaccine Dose 1
-
XW023S6Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
-
-
XW023S Iobenguane I-131 Antineoplastic
-
XW023S6Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
-
-
XW023T COVID-19 Vaccine Dose 2
-
XW023T6Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
-
-
XW023T Ruxolitinib
-
XW023T6Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
-
-
XW023U COVID-19 Vaccine
-
XW023U6Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
-
-
XW023U Imipenem-cilastatin-relebactam Anti-infective
-
XW023U6Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
-
-
XW023V COVID-19 Vaccine Dose 3
-
XW023V7Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
-
-
XW023V Gilteritinib Antineoplastic
-
XW023V7Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
-
-
XW023W Caplacizumab
-
XW023W7Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
-
-
XW023W COVID-19 Vaccine Booster
-
XW023W7Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
-
-
XW023X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW023X7Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
-
-
XW023X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW023X7Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
-
-
XW023Y Other New Technology Monoclonal Antibody
-
XW023Y7Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
-
-
-
XW027 Via Natural or Artificial Opening
-
XW0270 Brexanolone
-
XW0270 Spesolimab Monoclonal Antibody
-
XW0271 Daratumumab and Hyaluronidase-fihj
-
XW0271 Eladocagene exuparvovec
-
XW0272 Bromelain-enriched Proteolytic Enzyme
-
XW0272 Nerinitide
-
XW0273 Durvalumab Antineoplastic
-
XW0273 Maribavir Anti-infective
-
XW0274 Teclistamab Antineoplastic
-
XW0275 Mosunetuzumab Antineoplastic
-
XW0275 Narsoplimab Monoclonal Antibody
-
XW0276 Afamitresgene Autoleucel Immunotherapy
-
XW0276 Lefamulin Anti-infective
-
XW0276 Terlipressin
-
XW0277 Coagulation Factor Xa, Inactivated
-
XW0277 Tabelecleucel Immunotherapy
-
XW0277 Trilaciclib
-
XW0278 Lurbinectedin
-
XW0278 Mineral-based Topical Hemostatic Agent
-
XW0278 Treosulfan
-
XW0278 Uridine Triacetate
-
XW0279 Ceftolozane/Tazobactam Anti-infective
-
XW0279 Inebilizumab-cdon
-
XW0279 Satralizumab-mwge
-
XW027A Cefiderocol Anti-infective
-
XW027A Ciltacabtagene Autoleucel
-
XW027B Amivantamab Monoclonal Antibody
-
XW027B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW027B Omadacycline Anti-infective
-
XW027C Eculizumab
-
XW027C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW027D Atezolizumab Antineoplastic
-
XW027D Engineered Allogeneic Thymus Tissue
-
XW027E Etesevimab Monoclonal Antibody
-
XW027E Remdesivir Anti-infective
-
XW027F Bamlanivimab Monoclonal Antibody
-
XW027F Other New Technology Therapeutic Substance
-
XW027G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW027G Plazomicin Anti-infective
-
XW027G REGN-COV2 Monoclonal Antibody
-
XW027G Sarilumab
-
XW027H Axicabtagene Ciloleucel Immunotherapy
-
XW027H Other New Technology Monoclonal Antibody
-
XW027H Synthetic Human Angiotensin II
-
XW027H Tocilizumab
-
XW027J Apalutamide Antineoplastic
-
XW027J Tisagenlecleucel Immunotherapy
-
XW027K Fosfomycin Anti-infective
-
XW027K Idecabtagene Vicleucel Immunotherapy
-
XW027K Leronlimab Monoclonal Antibody
-
XW027L CD24Fc Immunomodulator
-
XW027L Erdafitinib Antineoplastic
-
XW027L Lifileucel Immunotherapy
-
XW027M Baricitinib
-
XW027M Brexucabtagene Autoleucel Immunotherapy
-
XW027M Esketamine Hydrochloride
-
XW027N Lisocabtagene Maraleucel Immunotherapy
-
XW027N Meropenem-vaborbactam Anti-infective
-
XW027P Antibiotic-eluting Bone Void Filler
-
XW027Q Tagraxofusp-erzs Antineoplastic
-
XW027R Fostamatinib
-
XW027R Venetoclax Antineoplastic
-
XW027S COVID-19 Vaccine Dose 1
-
XW027S Iobenguane I-131 Antineoplastic
-
XW027T COVID-19 Vaccine Dose 2
-
XW027T Ruxolitinib
-
XW027U COVID-19 Vaccine
-
XW027U Imipenem-cilastatin-relebactam Anti-infective
-
XW027V COVID-19 Vaccine Dose 3
-
XW027V Gilteritinib Antineoplastic
-
XW027W Caplacizumab
-
XW027W COVID-19 Vaccine Booster
-
XW027X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW027X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW027Y Other New Technology Monoclonal Antibody
-
-
XW028 Via Natural or Artificial Opening Endoscopic
-
XW0280 Brexanolone
-
XW0280 Spesolimab Monoclonal Antibody
-
XW0281 Daratumumab and Hyaluronidase-fihj
-
XW0281 Eladocagene exuparvovec
-
XW0282 Bromelain-enriched Proteolytic Enzyme
-
XW0282 Nerinitide
-
XW0283 Durvalumab Antineoplastic
-
XW0283 Maribavir Anti-infective
-
XW0284 Teclistamab Antineoplastic
-
XW0285 Mosunetuzumab Antineoplastic
-
XW0285 Narsoplimab Monoclonal Antibody
-
XW0286 Afamitresgene Autoleucel Immunotherapy
-
XW0286 Lefamulin Anti-infective
-
XW0286 Terlipressin
-
XW0287 Coagulation Factor Xa, Inactivated
-
XW0287 Tabelecleucel Immunotherapy
-
XW0287 Trilaciclib
-
XW0288 Lurbinectedin
-
XW0288 Mineral-based Topical Hemostatic Agent
-
XW0288 Treosulfan
-
XW0288 Uridine Triacetate
-
XW0289 Ceftolozane/Tazobactam Anti-infective
-
XW0289 Inebilizumab-cdon
-
XW0289 Satralizumab-mwge
-
XW028A Cefiderocol Anti-infective
-
XW028A Ciltacabtagene Autoleucel
-
XW028B Amivantamab Monoclonal Antibody
-
XW028B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW028B Omadacycline Anti-infective
-
XW028C Eculizumab
-
XW028C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW028D Atezolizumab Antineoplastic
-
XW028D Engineered Allogeneic Thymus Tissue
-
XW028E Etesevimab Monoclonal Antibody
-
XW028E Remdesivir Anti-infective
-
XW028F Bamlanivimab Monoclonal Antibody
-
XW028F Other New Technology Therapeutic Substance
-
XW028G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW028G Plazomicin Anti-infective
-
XW028G REGN-COV2 Monoclonal Antibody
-
XW028G Sarilumab
-
XW028H Axicabtagene Ciloleucel Immunotherapy
-
XW028H Other New Technology Monoclonal Antibody
-
XW028H Synthetic Human Angiotensin II
-
XW028H Tocilizumab
-
XW028J Apalutamide Antineoplastic
-
XW028J Tisagenlecleucel Immunotherapy
-
XW028K Fosfomycin Anti-infective
-
XW028K Idecabtagene Vicleucel Immunotherapy
-
XW028K Leronlimab Monoclonal Antibody
-
XW028L CD24Fc Immunomodulator
-
XW028L Erdafitinib Antineoplastic
-
XW028L Lifileucel Immunotherapy
-
XW028M Baricitinib
-
XW028M Brexucabtagene Autoleucel Immunotherapy
-
XW028M Esketamine Hydrochloride
-
XW028N Lisocabtagene Maraleucel Immunotherapy
-
XW028N Meropenem-vaborbactam Anti-infective
-
XW028P Antibiotic-eluting Bone Void Filler
-
XW028Q Tagraxofusp-erzs Antineoplastic
-
XW028R Fostamatinib
-
XW028R Venetoclax Antineoplastic
-
XW028S COVID-19 Vaccine Dose 1
-
XW028S Iobenguane I-131 Antineoplastic
-
XW028T COVID-19 Vaccine Dose 2
-
XW028T Ruxolitinib
-
XW028U COVID-19 Vaccine
-
XW028U Imipenem-cilastatin-relebactam Anti-infective
-
XW028V COVID-19 Vaccine Dose 3
-
XW028V Gilteritinib Antineoplastic
-
XW028W Caplacizumab
-
XW028W COVID-19 Vaccine Booster
-
XW028X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW028X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW028Y Other New Technology Monoclonal Antibody
-
-
XW02X External
-
XW02X0 Brexanolone
-
XW02X0 Spesolimab Monoclonal Antibody
-
XW02X1 Daratumumab and Hyaluronidase-fihj
-
XW02X1 Eladocagene exuparvovec
-
XW02X2 Bromelain-enriched Proteolytic Enzyme
-
XW02X2 Nerinitide
-
XW02X3 Durvalumab Antineoplastic
-
XW02X3 Maribavir Anti-infective
-
XW02X4 Teclistamab Antineoplastic
-
XW02X5 Mosunetuzumab Antineoplastic
-
XW02X5 Narsoplimab Monoclonal Antibody
-
XW02X6 Afamitresgene Autoleucel Immunotherapy
-
XW02X6 Lefamulin Anti-infective
-
XW02X6 Terlipressin
-
XW02X7 Coagulation Factor Xa, Inactivated
-
XW02X7 Tabelecleucel Immunotherapy
-
XW02X7 Trilaciclib
-
XW02X8 Lurbinectedin
-
XW02X8 Mineral-based Topical Hemostatic Agent
-
XW02X8 Treosulfan
-
XW02X8 Uridine Triacetate
-
XW02X9 Ceftolozane/Tazobactam Anti-infective
-
XW02X9 Inebilizumab-cdon
-
XW02X9 Satralizumab-mwge
-
XW02XA Cefiderocol Anti-infective
-
XW02XA Ciltacabtagene Autoleucel
-
XW02XB Amivantamab Monoclonal Antibody
-
XW02XB Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW02XB Omadacycline Anti-infective
-
XW02XC Eculizumab
-
XW02XC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW02XD Atezolizumab Antineoplastic
-
XW02XD Engineered Allogeneic Thymus Tissue
-
XW02XE Etesevimab Monoclonal Antibody
-
XW02XE Remdesivir Anti-infective
-
XW02XF Bamlanivimab Monoclonal Antibody
-
XW02XF Other New Technology Therapeutic Substance
-
XW02XG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW02XG Plazomicin Anti-infective
-
XW02XG REGN-COV2 Monoclonal Antibody
-
XW02XG Sarilumab
-
XW02XH Axicabtagene Ciloleucel Immunotherapy
-
XW02XH Other New Technology Monoclonal Antibody
-
XW02XH Synthetic Human Angiotensin II
-
XW02XH Tocilizumab
-
XW02XJ Apalutamide Antineoplastic
-
XW02XJ Tisagenlecleucel Immunotherapy
-
XW02XK Fosfomycin Anti-infective
-
XW02XK Idecabtagene Vicleucel Immunotherapy
-
XW02XK Leronlimab Monoclonal Antibody
-
XW02XL CD24Fc Immunomodulator
-
XW02XL Erdafitinib Antineoplastic
-
XW02XL Lifileucel Immunotherapy
-
XW02XM Baricitinib
-
XW02XM Brexucabtagene Autoleucel Immunotherapy
-
XW02XM Esketamine Hydrochloride
-
XW02XN Lisocabtagene Maraleucel Immunotherapy
-
XW02XN Meropenem-vaborbactam Anti-infective
-
XW02XP Antibiotic-eluting Bone Void Filler
-
XW02XQ Tagraxofusp-erzs Antineoplastic
-
XW02XR Fostamatinib
-
XW02XR Venetoclax Antineoplastic
-
XW02XS COVID-19 Vaccine Dose 1
-
XW02XS Iobenguane I-131 Antineoplastic
-
XW02XT COVID-19 Vaccine Dose 2
-
XW02XT Ruxolitinib
-
XW02XU COVID-19 Vaccine
-
XW02XU Imipenem-cilastatin-relebactam Anti-infective
-
XW02XV COVID-19 Vaccine Dose 3
-
XW02XV Gilteritinib Antineoplastic
-
XW02XW Caplacizumab
-
XW02XW COVID-19 Vaccine Booster
-
XW02XX Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW02XX Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW02XY Other New Technology Monoclonal Antibody
-
-